HiPSC-derived cardiac tissue for disease modeling and drug discovery

Li, Junjun; Hua, Ying; Miyagawa, Shigeru et al.

International Journal of Molecular Sciences, 2020, 21(23), 8893

Number of Access:1,273（2025-08-15 13:21 Counts）

Identifier to cite or link to this item: https://hdl.handle.net/11094/78289

Link to primary information 

File Format Terms of use Size Views Date.Available Description information
ijms_21_23_8893 pdf None 768 KB 295 2021.01.15  
Creative Commons : Attribution

Item Information

Output File Export EndNote Basic Export Mendeley

Title
HiPSC-derived cardiac tissue for disease modeling and drug discovery
Creator
NRID
1000010723786 1000010723786
ORCID
0000-0002-7473-4918 0000-0002-7473-4918
researchmap permalink
liJJ liJJ
Scopus Author ID
52464043600 52464043600
CreatorName
Li, Junjun
CreatorName
Hua, Ying
NRID
1000070544237 1000070544237
ORCID
0000-0003-0015-6569 0000-0003-0015-6569
researchmap permalink
s-miyagawa3154 s-miyagawa3154
Scopus Author ID
55560624700 55560624700
CreatorName
Miyagawa, Shigeru
CreatorName
Zhang, Jingbo
CreatorName
Li, Lingjun
NRID
1000050380093 1000050380093
researchmap permalink
7000008694 7000008694
Scopus Author ID
55628530013 55628530013
CreatorName
Liu, Li
NRID
1000000243220 1000000243220
researchmap permalink
y-sawa0703 y-sawa0703
Scopus Author ID
55428162700 55428162700
CreatorName
Sawa, Yoshiki
Subject
Disease modeling
Drug discovery
HiPSC-derived cardiomyocytes
Maturation
Subtype
Description
Li, J.; Hua, Y.; Miyagawa, S.; Zhang, J.; Li, L.; Liu, L.; Sawa, Y. hiPSC-Derived Cardiac Tissue for Disease Modeling and Drug Discovery. Int. J. Mol. Sci. 2020, 21, 8893.
Abstract
Relevant, predictive normal, or disease model systems are of vital importance for drug development. The difference between nonhuman models and humans could contribute to clinical trial failures despite ideal nonhuman results. As a potential substitute for animal models, human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes (CMs) provide a powerful tool for drug toxicity screening, modeling cardiovascular diseases, and drug discovery. Here, we review recent hiPSC-CM disease models and discuss the features of hiPSC-CMs, including subtype and maturation and the tissue engineering technologies for drug assessment. Updates from the international multisite collaborators/administrations for development of novel drug discovery paradigms are also summarized.
Publisher
MDPI AG
Source Title
International Journal of Molecular Sciences
Volume (Issue)
21(23)
Page
8893
Date of Issued
2020-11-24
Language
English
Handle URL
https://hdl.handle.net/11094/78289
PISSN
16616596
eISSN
14220067
NCID
AA12038549
Relation.isIdenticalTo
DOI (Publisher Version)
https://doi.org/10.3390/ijms21238893
PMID
33255277
Access Rights
open access
CopyRight
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is licensed under a Creative Commons Attribution 4.0 International License.
oaire:version
Version of Record
Category
学術雑誌論文 Journal Article